Diethyl propionyl phosphate | 91997-23-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: Diethyl propionyl phosphate
• 英文别名: ethyl diethoxyphosphoryl formate；Propionyl-phosphorsaeure-diaethylester；Ethyl-diethoxyphosphinyl-format；O-Propionyl-O,O-diethylphosphat；Phosphorsaeure-diaethylester-propionsaeure-anhydrid；propionyl-phosphoric acid diethyl ester；Methyl diethyl phosphono acetate；Diethoxyphosphoryl propanoate
• CAS: 91997-23-8
• 化学式: C₇H₁₅O₅P
• 分子量: 210.167
• InChiKey: UTJLHRMUKPTBEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Diethyl propionyl phosphate 在 三甲基溴硅烷 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以100%的产率得到ethoxycarbonylphosphonic acid
  参考文献：
  名称：

  一种丙泊酚磷酰胺衍生物、其制备方法及其在医药上的用途

  摘要：

  一种丙泊酚磷酰胺衍生物、其制备方法及其在医药上的用途。本发明涉及一种通式(I)所示化合物及其立体异构体或药学上可接受的盐，以及医药中的应用，通式(I)化合物的结构如下所示，其基团定义与说明书定义一致。

  公开号：

  CN112390821A
• 作为产物：
  描述：

  diethyl (1-oxopropyl)phosphonate 在 双氧水 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 以90%的产率得到Diethyl propionyl phosphate
  参考文献：
  名称：

  Acyl phosphates from acyl phosphonates. A novel Baeyer-Villiger rearrangement

  摘要：

  The mechanism of a novel Baeyer-Villiger rearrangement, characterized by a stereospecific migration of a phosphoryl moiety to a peroxy oxygen, provides an extraordinarily efficient synthetic route to acyl phosphates. The mechanistic subtleties associated with this rearrangement have been explored using O-17-enriched hydrogen peroxide (H-2*O2) as the mechanistic probe with O-17 NMR spectroscopy as the analytical tool.

  DOI：

  10.1021/jo00069a004

文献信息

• [EN] N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE<br/>[FR] DÉRIVÉS DE N-ARYLE ET DE N-HÉTÉROARYLE PIPÉRIDINE EN TANT QU'AGONISTES DES RÉCEPTEURS HÉPATIQUES X, COMPOSITIONS ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2018068297A1

  公开（公告）日：2018-04-19

  Provided herein are certain substituted N-aryl and N-heteroaryl piperidine compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, L1, Q, R5 and R 6 are as defined. The said novel compounds, and pharmaceutically acceptable compositions comprising a compound thereof, may be useful as Liver X-β receptor(LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory disease and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

  提供的是某些取代的N-芳基和N-杂芳基哌啶化合物，其化学式为(I)以及药用可接受的盐，其中R1、R2、R3、L、R4、L1、Q、R5和R6定义如所述。所述新颖化合物，以及包含其化合物的药用可接受组合物，可能用作肝X-β受体(LXRβ)激动剂，并可用于治疗或预防与之相关的病理学。这类病理学包括但不限于炎症性疾病和以胆固醇和脂质代谢缺陷为特征的疾病，例如阿尔茨海默病。
• [EN] ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE<br/>[FR] DÉRIVÉS D'ETHER D'ARYL ET D'HETEROARYLE EN TANT QU'AGONISTES DES RÉCEPTEURS Β X DU FOIE, COMPOSITIONS ET UTILISATION ASSOCIÉE
  申请人：MERCK SHARP & DOHME

  公开号：WO2018068295A1

  公开（公告）日：2018-04-19

  Substituted aryl and heteroaryl ether compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R 1, R 2, R 3, L, R 4, L 1, Q, and R 5 are as defined herein. These compounds and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

  式(I)中的取代芳基和杂环芳基醚化合物及其药用盐，其中X、R1、R2、R3、L、R4、L1、Q和R5如本文所定义。这些化合物和含有其化合物的药用组合物可用作肝X-β受体(LXRβ)激动剂，并可能用于治疗或预防与之相关的病理。这些病理包括但不限于炎症性疾病和以胆固醇和脂质代谢缺陷为特征的疾病，如阿尔茨海默病。
• Adenosine receptor antagonists and methods of making and using the same
  申请人：Biogen, Incorporated

  公开号：US06605600B1

  公开（公告）日：2003-08-12

  The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula I: R3 is an optionally substituted group selected from: and wherein X1, X2, Z, R1, R2, and R6 are as described in the specification.

  这项发明基于发现，式I化合物意外地具有非常高的潜在和选择性抑制腺苷A1受体的作用。腺苷A1受体拮抗剂可用于预防和/或治疗多种疾病，包括心脏和循环系统疾病、中枢神经系统退行性疾病、呼吸系统疾病以及适用于利尿治疗的许多疾病。在一种实施例中，该发明涉及一种式I化合物：R3是从中选择的可选取代基团，其中X1、X2、Z、R1、R2和R6如规范中所述。
• Technical field
  申请人：NeuroSearch A/S

  公开号：US20030166638A1

  公开（公告）日：2003-09-04

  Chemical compounds of the formula 1 as well as pharmaceutical compositions containing them and methods for their use in the treatment of disorders and diseases responsive to modulation of the GABA A receptor complex of the central nervous system, such disorders and diseases including anxiety, sleep disorders, anesthesia, memory disorders, and epilepsy and other convulsive disorders.

  化学式为1的化合物，以及含有它们的制药组合物和使用它们治疗对中枢神经系统的GABAA受体复合物调节敏感的疾病和疾病的方法，这些疾病包括焦虑症、睡眠障碍、麻醉、记忆障碍、癫痫和其他惊厥性疾病。
• Process for the production of ramoplanin-like amide derivatives
  申请人：Ciabatti Romeo

  公开号：US20050106691A1

  公开（公告）日：2005-05-19

  The invention regards a process for the production of ramoplanin-like derivatives of formula (I): RAMO-NC—CO—R (I), wherein the radical R represents a hydrocarbon radical and the portion RAMO-NH— represents deacylated ramoplanin, any of its factors or ramoplanose. The compound of Formula (I) are obtained by reacting a carboxylic acid R—COOH with deacylated ramoplanin, any of its factors or ramoplanose protected on the ornitine amino groups. New compounds wherein the hydrocarbon radical R is different form those characaterizing the ramoplanin and ramoplanose natural products and their tetrahydro-derivatives are calimed. The new compounds have the same or better antinfective activity, lower haemolytic effect and better tolerability profile than ramoplanin.

  该发明涉及一种制备公式（I）RAMO-NC-CO-R的类似于拉莫普兰（ramoplanin）的衍生物的过程，其中基团R代表一个碳氢基团，RAMO-NH-部分代表去酰化的拉莫普兰、其任何因子或拉莫普兰糖。通过将羧酸R-COOH与保护在鸟氨酸氨基上的去酰化拉莫普兰、其任何因子或拉莫普兰糖反应得到公式（I）的化合物。声明了新的化合物，其中碳氢基团R与拉莫普兰和拉莫普兰糖天然产物及其四氢衍生物所特征的基团不同。新化合物具有与拉莫普兰相同或更好的抗感染活性，较低的溶血效应和更好的耐受性特征。